Mast Therapeutics to buy blood-pressure firm Aires

Mast Therapeutics (MSTX) has agreed to acquire Aires Pharmaceuticals, a privately held clinical-stage company developing therapies for pulmonary vascular disorders, in an all-stock deal.

Aires' lead product, AIR001, has orphan-drug status in the U.S. and Europe for pulmonary arterial hypertension.

Under the terms of the transaction, Aires will receive shares representing 6% of Mast's commons stock.

Adam Feuerstein tweets that Mast is "paying 6M shares of stock for Aires, or roughly $5M." Feuerstein also notes that Novartis had an option to acquire Aires but has apparently decided not to take it.

Notwithstanding, Mast's shares are +5%. (PR)

Comments (1)
  • jetpilotdan
    , contributor
    Comments (36) | Send Message
    Will Novartis partner up with mstx now that air001 can complete phase 2 & 3 goals?
    14 Sep 2014, 12:20 PM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs